Physician profile
Amenze A Oriaifo
NPI 1629496641
$17,712.29
in general payments reported to CMS, 2019-2025
27 companies · $4,600 in 2025
The $4,600 reported for 2025 was more than what 89% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $421 · 2021: $341 · 2022: $7,142 · 2023: $2,152 · 2024: $2,126 · 2025: $4,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,690 · Consulting Fee: $1,100 · Long Term Medical Supply Or Device Loan: $64.25 · Education: $23.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,689.80 |
| Consulting Fee | $1,100.00 |
| Long Term Medical Supply Or Device Loan | $64.25 |
| Education | $23.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,659.43 | 2019-2022 | |
| Abbvie INC. | $2,762.00 | 2022-2025 | |
| Alcon Vision LLC | $1,973.96 | 2019-2025 | Hydrus Microstent, Lensx, Rocklatan |
| Bausch & Lomb Americas INC. | $1,188.67 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| New World Medical,INC. | $806.08 | 2022-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Sight Sciences, INC. | $800.25 | 2021-2025 | Omni Surgical System |
| Ocular Therapeutix, INC. | $678.54 | 2023-2025 | Dextenza |
| Rxsight INC | $612.28 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Glaukos Corporation | $549.54 | 2019-2025 | Idosetr, Istent Infinite |
| Ellexiscience | $331.22 | 2019 | |
| Amgen INC. | $326.07 | 2025 | Tepezza |
| Regeneron Pharmaceuticals, INC. | $149.94 | 2023 | Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.63 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $126.94 | 2019-2023 | One Series Ultra |
| Biotissue Holdings INC. | $107.05 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $71.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $65.99 | 2021-2023 | |
| Carl Zeiss Meditec USA, INC. | $64.25 | 2023 | Cirrus Hd-Oct |
| Horizon Therapeutics Plc | $57.86 | 2019-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $53.43 | 2025 | Xdemvy |
| Astellas Pharma US INC | $51.52 | 2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $36.80 | 2019-2021 | |
| Oyster Point Pharma, INC. | $30.90 | 2023 | Tyrvaya |
| Omeros Corporation | $19.74 | 2019 | |
| Thea Pharma INC. | $17.50 | 2025 | Iyuzeh |
| Tearlab Corp | $14.93 | 2023 | Tearlab Osmolarity System |
| Eyevance Pharmaceuticals LLC | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amenze Oriaifo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.